CA
LCTX icon

Commerzbank Aktiengesellschaft’s Lineage Cell Therapeutics LCTX Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-48,164
Closed -$164K – 1008
2016
Q3 		$164K Buy
+48,164
New +$133K ﹤0.01% 864

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Commerzbank Aktiengesellschaft's LCTX Position: Q4 2016 in Review

Commerzbank Aktiengesellschaft sold out of Lineage Cell Therapeutics (LCTX) in Q4 2016, closing a stake of 48,164 shares — an estimated $164K sold.

Commerzbank Aktiengesellschaft first reported a position in LCTX in Q3 2016 and held it in 1 quarter. The position peaked at $164K in Q3 2016. 92 funds tracked by Wall St. Rank hold LCTX as of Q4 2016.

  • Commerzbank Aktiengesellschaft reported no remaining Lineage Cell Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Commerzbank Aktiengesellschaft sold 48,164 Lineage Cell Therapeutics shares in Q4 2016, an estimated $164K.
  • Commerzbank Aktiengesellschaft first reported a position in Lineage Cell Therapeutics in Q3 2016 and held it in 1 quarter.
  • Commerzbank Aktiengesellschaft's Lineage Cell Therapeutics position peaked at $164K in Q3 2016.
  • 92 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2016.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q4 2016, filed 7 Feb 2017.